WATERTOWN, Mass.-Dicerna Pharmaceuticals, Inc., a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™, today announced presentations at two upcoming conferences: the RNAi World Congress 2009, May 14-15, in Boston; and TIDES® 2009, the Oligonucleotide and Peptide Technology and Product Development Conference, May 17-20, in Las Vegas.
Dicerna at RNAi World Congress 2009:
In a podium presentation titled “Potent In Vivo Activity of Dicer Substrate siRNAs (DsiRNA) Targeting KRAS,” Bob D. Brown, Ph.D., Dicerna’s senior vice president of research, will highlight preclinical findings demonstrating highly selective, specific and potent inhibition using novel DsiRNAs against KRAS, a gene that plays a central role in the growth, differentiation, and survival of cells. KRAS gene mutations are associated with multiple cancers, including leukemias, and lung, colorectal and pancreatic tumors. Dr. Brown will highlight the potent in vivo activity and pharmaceutical properties of DsiRNAs that lead to their enhanced drug delivery potential. This presentation is scheduled for 2:15 p.m. (EDT) on Thursday, May 14, 2009.
Also, in a podium presentation titled “Developing Dicer-Substrate siRNA Drugs,” Mark Behlke, M.D., Ph.D, chief scientific officer at Integrated DNA Technologies (IDT) and Dicerna scientific co-founder, will discuss IDT’s collaborative work with Dicerna to systematically screen over 400 DsiRNAs to identify ultra-potent sites in the human and mouse KRAS genes. Dr. Behlke is a Dicerna co-founder and scientific advisory board member. This presentation is scheduled for 1:45 p.m. (EDT) on Thursday, May 14, 2009.
Dicerna at TIDES 2009:
Dr. Brown will be presenting at the TIDES Main Conference on the subject of “DsiRNA versus siRNA Entry and Triggering of RNAi,” demonstrating that inhibition of gene expression by DsiRNA is of more potent and longer duration than inhibition induced by typical 21mer siRNA. Dr. Brown will also provide a systematic comparison of the molecular and mechanistic differences of the RNA and protein components of RISC loaded by cognate DsiRNA, siRNA, and other RNAi trigger configurations, including in vitro and in vivo data. This presentation is scheduled for 2 p.m. (PDT) on Wednesday, May 20 as part of the Oligonucleotides session.
As part of this session, Dr. Brown will also present chairperson’s remarks on the subject of “Development Strategies of Leading Oligos in Clinical Development” at 3 p.m.
No comments:
Post a Comment